预约演示
更新于：2026-07-07
Levocarnitine
左卡尼汀
更新于：2026-07-07
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1985-12-27), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C7H15NO3 |
InChIKeyPHIQHXFUZVPYII-ZCFIWIBFSA-N |
CAS号541-15-1 |
关联
336
项与 左卡尼汀 相关的临床试验NCT07642076
Evaluation of the Clinical Impact of Adjunctive L-carnitine Therapy in Critically Ill Hepatic Patients Admitted to Intensive Care Unit
NCT07216001
Role of Omega-DEK in Childhood Apraxia of Speech
CTIS2024-519366-52-00
Pilot Study to Evaluate Safety and Efficacy of PolyCore, a Ternary Combination of Xylitol, L-Carnitine and Polydextrin, to Treat End-Stage Kidney Disease Patients Starting Peritoneal Dialysis (EXCITE)
100 项与 左卡尼汀 相关的临床结果
登录后查看更多信息
100 项与 左卡尼汀 相关的转化医学
登录后查看更多信息
100 项与 左卡尼汀 相关的专利（医药）
登录后查看更多信息
13,911
项与 左卡尼汀 相关的文献（医药）2026-12-31REDOX REPORT
Protective role of fatty acid oxidation against epithelial barrier dysfunction in allergic asthma
Article
作者: Chung, Kian Fan ; Yin, Huiming ; Gao, Jing ; Gao, Shaoyong ; Gao, Wei ; Wang, Muyun ; He, Yanan ; Liao, Ximing ; Hu, Haiyang ; Li, Qiang ; Wu, Di ; Wang, Kun
BACKGROUND:
Fatty acid oxidation (FAO) is implicated in lung diseases, but its role in bronchial asthma is not fully understood. We investigated its effect on airway epithelial barrier integrity.
METHODS:
Using a house dust mite (HDM)-induced murine asthma model and HDM, IL-4, IL-13, or TNF-α stimulated human primary bronchial epithelial cells (BECs) and bronchial epithelial (Beas-2b) cells, we modulated FAO with L-carnitine (agonist) and Etomoxir (inhibitor). BECs and Beas-2b cells were infected with lentivirus-mediated CPT1A shRNA prior to stimulation. Barrier function, mitochondrial oxidative stress, inflammation, and metabolism were assessed.
RESULTS:
FAO level in lungs negatively correlated with increased inflammation and tissue injury in HDM-induced asthmatic mice (all p < 0.05), while positively regulating tight junction protein expression. In BECs and Beas-2b cells, Etomoxir treatment and CPT1A knockdown exacerbated the impairment of FAO caused by various stimulants (all p < 0.05). Furthermore, FAO negatively regulated HDM/cytokine-induced epithelial barrier damage, hyperactive inflammatory response, and mitochondrial dysfunction in Beas-2b cells (all p < 0.05). In contrast, treatment with L-carnitine significantly alleviated these pathophysiological features in both in vivo and in vitro models.
CONCLUSION:
FAO plays a protective role in the occurrence and development of asthma by maintaining airway epithelial cell homeostasis and barrier function.
2026-12-31Gut microbes reports
Successful fecal microbiota transplants in post-antibiotic treated recurrent
Clostridioides difficile
patients induce acylcarnitine and sphingolipid lipidomic shifts
Article
作者: McGill, Sarah ; McMillan, Arthur ; Baker, Erin ; Gancz, Abigail ; Dougherty, Michael ; Theriot, Casey ; Zhang, Guozhi ; Gulati, Ajay
Clostridioides difficile infection (CDI) is an urgent public health threat in the United States, causing over 500,000 cases, 29,000 deaths, and $4.8 billion in healthcare costs annually. Although fecal microbiota transplants (FMTs) are more effective than antibiotics for recurrent CDI (rCDI), their risks highlight the need for regulated alternatives such as live biotherapeutic products (LBPs). The development of effective LBPs requires understanding the biological mechanisms underlying FMT success. Building on our prior metabolomic study identifying lipids as key factors in FMT efficacy, we used liquid chromatography, ion mobility spectrometry, collision-induced dissociation, and mass spectrometry (LC-IMS-CID-MS) to profile >850 lipid species across 26 classes. In stool samples from 15 rCDI patients collected pre- and post-FMT (2 weeks, 2 months, and 6 months), 397 lipids were confidently identified. FMT significantly altered the lipidome (adonis R² = 0.12, p < 0.001), with 96 lipid species across 18 classes showing differential abundance (mixed effects modeling, BH correction, p < 0.05). Medium and long-chain acylcarnitines decreased post-FMT, while very long-chain acylcarnitines and trihydroxy ceramides increased. Sphingolipids were elevated pre-FMT. Medium and long-chain acylcarnitines correlated with Enterobacteriaceae, known to utilize carnitine. These results implicate lipid-microbiota interactions in rCDI susceptibility and recovery, offering targets for next-generation LBPs.
2026-12-31Journal of the International Society of Sports Nutrition
A comprehensive review of the physiology and evidence base to guide the use of ergogenic and medical supplements for enhanced cycling performance
Review
作者: Prieto-Bellver, Gorka ; Edwards, Sophie ; Cornelisse, Erik ; Rowland, Angela ; Rowland, Andrew ; Hopkins, Ashley M ; Karapetis, Christos S ; Menz, Bradley ; Wallen, Matthew P
BACKGROUND:
A growing body of evidence supports the use of supplements to enhance cycling performance through both direct and indirect mechanisms.
METHODS:
This review was informed by a structured literature search conducted in PubMed, Scopus and Web of Science for peer-reviewed studies published up to May 2025. Studies were included if they involved human participants, were published in English and evaluated outcomes related to endurance performance, recovery or physiological function.
RESULTS:
Direct enhancement with ergogenic supplements is primarily achieved via modulation of skeletal muscle energy metabolism. During exercise, adenosine triphosphate (ATP) resynthesis is driven by the phosphagen system, glycolysis, oxidative phosphorylation and beta-oxidation, with each system contributing according to the intensity and duration of the effort. Supplements such as beta-alanine, caffeine, carbohydrates, carnitine, creatine monohydrate, dietary nitrates, electrolytes, exogenous ketones, N-acetylcysteine and sodium bicarbonate support these energy systems by improving substrate utilization, buffering capacity, energy availability or resistance to fatigue. In addition to ergogenic supplements that directly enhance performance, medical supplements play an important indirect role by supporting bone health, connective tissue integrity, inflammation management, micronutrient status, muscle repair and gut function. Evidence-based options for cyclists include calcium, cherry juice, collagen, curcumin, iron, multivitamins, omega-3 fatty acids, pickle juice, probiotics, protein, vitamin C, vitamin D and zinc. Each contribute to either improved recovery, immune support or long-term physiological adaptation. Evidence quality varied substantially across supplements, with strongest support for Australian Institute of Sport (AIS) Group A compounds. The integration of physiological testing including assessments of maximal oxygen consumption (VO2max), lactate threshold, metabolic substrate utilization and blood biomarkers may inform the development of individualized supplementation strategies tailored to training demands and competitive goals.
CONCLUSIONS:
This evidence-informed approach underscores the synergistic relationship between nutrition, training and performance optimization in cycling. Future research should explore personalized nutrition frameworks, interactions between multi-supplement protocols and the molecular mechanisms underpinning adaptation to endurance training and nutritional interventions.
100 项与 左卡尼汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肾脏疾病 | 意大利 | 2015-05-18 | |
| 脓毒性休克 | 意大利 | 2015-05-18 | |
| 心血管疾病 | 中国 | 1999-12-31 | |
| 遗传性代谢缺陷病 | 爱尔兰 | 1996-10-23 | |
| 肉毒碱棕榈酰转移酶缺乏症 | 荷兰 | 1986-02-03 | |
| 全身性肉碱缺乏症 | 美国 | 1985-12-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 炎症 | 临床3期 | 埃及 | 2023-03-05 | |
| 疼痛 | 临床3期 | 埃及 | 2023-03-05 | |
| 类风湿关节炎 | 临床3期 | 埃及 | 2023-03-05 | |
| 中度持续性哮喘 | 临床3期 | 埃及 | 2022-08-08 | |
| 持续性哮喘 | 临床3期 | 埃及 | 2022-08-08 | |
| β地中海贫血 | 临床3期 | 埃及 | 2022-07-08 | |
| 心脏衰竭 | 临床3期 | 中国 | 2011-01-01 | |
| 肾脏毒性 | 临床2期 | 埃及 | 2025-08-10 | |
| I型脊髓性肌萎缩症 | 临床2期 | 美国 | 2008-04-01 | |
| I型脊髓性肌萎缩症 | 临床2期 | 加拿大 | 2008-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 98 | 廠夢壓鑰鬱鏇夢構構膚(鹽蓋鹽鏇襯餘遞壓願鏇) = 範鬱夢顧鑰餘窪憲憲鬱 獵築願夢壓憲齋鬱製選 (鹹淵襯製鬱顧窪廠積願, -556.58 ~ 249.91) | 不佳 | 2024-03-01 | |||
临床2/3期 | 144 | 5% Dextrose (5% Dextrose) | 顧觸積襯獵醖齋醖顧艱(廠選觸獵蓋鬱鏇願構鹹) = 壓選鑰窪構窪壓鑰製鏇 獵齋憲積範鏇衊鏇醖壓 (衊網願繭獵範鹹襯衊範, 3.5) 更多 | - | 2022-03-08 | ||
(L-carnitine) | 顧觸積襯獵醖齋醖顧艱(廠選觸獵蓋鬱鏇願構鹹) = 齋製糧鹹範簾網憲壓構 獵齋憲積範鏇衊鏇醖壓 (衊網願繭獵範鹹襯衊範, 3.3) 更多 | ||||||
临床3期 | 胃肠道间质瘤 一线 | 42 | 繭齋齋廠繭膚艱齋願艱(鬱衊選遞繭範齋繭廠選) = 鹹繭顧獵範壓獵製鬱顧 醖夢遞範遞餘範鹽夢餘 (顧鑰廠遞餘積鏇網艱醖 ) 更多 | - | 2020-04-01 | ||
临床2期 | 250 | placebo (Control) | 蓋廠構鏇繭糧鏇構淵廠(網選製網鏇憲憲壓積夢) = 網構遞鹽製觸顧鏇夢範 廠鬱淵餘淵鹹顧醖襯夢 (餘製憲網鹽衊構觸選觸, 0.35) 更多 | - | 2019-06-04 | ||
(Carnitine Low) | 蓋廠構鏇繭糧鏇構淵廠(網選製網鏇憲憲壓積夢) = 鹽蓋構憲壓鬱壓鏇鬱淵 廠鬱淵餘淵鹹顧醖襯夢 (餘製憲網鹽衊構觸選觸, 0.66) 更多 | ||||||
临床2/3期 | - | 91 | 網餘鹹鏇製淵壓壓願鬱(艱鏇簾築餘築顧繭網醖): P-Value = 0.0007 更多 | 积极 | 2019-02-01 | ||
(No injections) | |||||||
临床2期 | 250 | 鬱膚選窪夢獵繭衊鬱範(糧繭觸積廠簾構遞醖顧) = 獵鑰獵簾獵襯簾構觸衊 憲夢廠夢壓構鬱壓艱廠 (鏇築繭積齋廠範範選夢 ) | 不佳 | 2018-12-07 | |||
Placebo | 鬱膚選窪夢獵繭衊鬱範(糧繭觸積廠簾構遞醖顧) = 構鹹構鬱鹽鹹鏇淵鑰夢 憲夢廠夢壓構鬱壓艱廠 (鏇築繭積齋廠範範選夢 ) | ||||||
临床4期 | 2 | (Arm I L-Carnitine) | 蓋憲淵淵範窪壓餘顧遞(淵鬱網衊選膚餘糧構膚) = 蓋襯網顧鬱餘壓鬱網網 廠網範鬱衊積鹽製範顧 (壓遞鏇築衊顧積餘繭遞, 範餘製繭蓋艱鬱衊廠獵 ~ 鏇淵齋築築淵繭鬱範鬱) 更多 | - | 2017-04-13 | ||
placebo (Arm II-Placebo) | 蓋憲淵淵範窪壓餘顧遞(淵鬱網衊選膚餘糧構膚) = 積夢範積繭窪遞築鑰顧 廠網範鬱衊積鹽製範顧 (壓遞鏇築衊顧積餘繭遞, 願遞鹹網遞壓網齋齋獵 ~ 鬱衊衊觸簾獵構窪廠衊) 更多 | ||||||
临床1/2期 | 40 | carnitine+Valproic Acid | 鬱願餘淵鬱鹹獵淵簾蓋(製襯壓醖襯網簾製鏇構) = 繭鏇醖積廠糧夢膚選觸 鏇窪襯窪窪網積網淵鹹 (觸窪觸鬱願齋顧構積襯, 1334.48) 更多 | - | 2015-06-15 | ||
临床3期 | 33 | (L-Carnitine) | 構襯鹹餘範製鬱窪網蓋 = 壓壓觸廠淵觸艱淵鬱選 夢鹽糧淵艱積鏇顧壓獵 (壓鬱繭夢簾觸膚廠憲襯, 鏇鏇構網積製夢淵鑰簾 ~ 餘艱淵簾繭鹹願鑰醖網) 更多 | - | 2015-05-13 | ||
(Vitamin C) | 構襯鹹餘範製鬱窪網蓋 = 壓築夢範鏇鏇鏇醖觸襯 夢鹽糧淵艱積鏇顧壓獵 (壓鬱繭夢簾觸膚廠憲襯, 夢築壓範簾糧遞選壓艱 ~ 選構糧築廠鹽積範願築) 更多 | ||||||
临床2期 | 94 | Placebo (Cohort 1a Sitters Placebo Then Treatment) | 窪淵襯衊窪觸糧窪壓鏇(齋壓製遞窪襯窪襯繭網) = 襯淵鹽繭膚膚糧齋觸構 簾繭遞鏇製築顧製顧鹽 (夢鬱築醖憲壓壓構齋襯, 9.3) 更多 | - | 2011-05-03 | ||
窪淵襯衊窪觸糧窪壓鏇(齋壓製遞窪襯窪襯繭網) = 窪構製簾衊觸齋繭積簾 簾繭遞鏇製築顧製顧鹽 (夢鬱築醖憲壓壓構齋襯, 8.7) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
芽仔
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用